N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy

J Hypertens. 2006 Aug;24(8):1531-9. doi: 10.1097/01.hjh.0000239288.10013.04.

Abstract

Background: N-terminal pro-brain natriuretic peptide (Nt-proBNP) and high-sensitivity C-reactive protein (hsCRP) are cardiovascular risk markers in various populations, but are not well examined in hypertension. Therefore, we wanted to investigate whether high Nt-proBNP or hsCRP predicted the composite endpoint of cardiovascular death, non-fatal stroke or non-fatal myocardial infarction independently of traditional cardiovascular risk factors and the urine albumin: creatinine ratio (UACR), which is a well established cardiovascular risk factor in hypertension.

Methods: In 945 hypertensive patients from the LIFE study with electrocardiographic left ventricular (LV) hypertrophy, we measured traditional cardiovascular risk factors including electrocardiography, morning UACR, hsCRP by immunoturbidimetry assay and Nt-proBNP by immunoassay after 2 weeks of placebo treatment. During 55 months' follow-up 80 patients suffered a composite endpoint.

Results: HsCRP as well as Nt-proBNP above the median values of 3.0 mg/l and 170 pg/ml, respectively, was associated with a higher incidence of composite endpoint (13.1 versus 3.8%, P < 0.01, and 11.5 versus 5.4%, P < 0.01). In Cox regression analyses, standardized log(hsCRP)/SD predicted a composite endpoint [hazard ratio (HR) 1.3 per SD = 0.47 log(mg/l), P < 0.05] after adjustment for traditional cardiovascular risk factors, but not after further adjustment for UACR. Standardized log(Nt-proBNP)/SD predicted a composite endpoint after adjustment for traditional cardiovascular risk factors [HR 1.9 per SD = 0.49 log(pg/ml), P < 0.05] as well as after further adjustment for UACR [HR 1.5 per SD = 0.49 log(pg/ml), P < 0.01]. Log(Nt-proBNP) added significantly to the Cox regression models using traditional cardiovascular risk factors with and without UACR (both P < 0.001).

Conclusion: Nt-proBNP predicted a composite endpoint after adjustment for traditional risk factors, UACR and a history of diabetes or cardiovascular disease and added significantly to the prediction of composite endpoint, whereas hsCRP did not.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Albumins / metabolism
  • Antihypertensive Agents / therapeutic use*
  • Atenolol / therapeutic use
  • Biomarkers / blood
  • Biomarkers / urine
  • C-Reactive Protein / metabolism*
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / metabolism
  • Confounding Factors, Epidemiologic
  • Creatinine / urine
  • Endpoint Determination
  • Female
  • Follow-Up Studies
  • Humans
  • Hypertension / blood
  • Hypertension / drug therapy*
  • Hypertension / epidemiology
  • Hypertension / metabolism*
  • Hypertension / urine
  • Hypertrophy, Left Ventricular / drug therapy
  • Hypertrophy, Left Ventricular / metabolism
  • Losartan / therapeutic use
  • Male
  • Middle Aged
  • Natriuretic Peptide, Brain / blood*
  • Peptide Fragments / blood*
  • Predictive Value of Tests
  • Proportional Hazards Models
  • ROC Curve
  • Risk Factors
  • Scandinavian and Nordic Countries / epidemiology

Substances

  • Albumins
  • Antihypertensive Agents
  • Biomarkers
  • Peptide Fragments
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • Atenolol
  • C-Reactive Protein
  • Creatinine
  • Losartan